HOME › DRUGS › RILZABRUTINIB
ACTIVE SUBSTANCE / INN

RILZABRUTINIB

Brand name(s): Wayrilz, WAYRILZ
FDA LISTED
EMA LISTED
PRESCRIPTION
AUTHORISED
Purpura, Thrombocytopenic, Idiopathic
NDA219685
ACTIVE SUBSTANCE
Rilzabrutinib
REGULATORS
FDA · EMA
SPONSORS / MAH
GENZYME CORP, Sanofi B.V.
TOTAL APPLICATIONS
2
FDA APPLICATIONS (DRUGS@FDA)
BRAND NAMEAPPLICATIONSPONSORSTATUS
WAYRILZNDA219685GENZYME CORPPrescription
EMA AUTHORISATIONS
PRODUCT NAMEHOLDERSTATUSDATEINDICATION
WayrilzSanofi B.V.Authorised22/12/2025Purpura, Thrombocytopenic, Idiopathic

FULL INTELLIGENCE ON RILZABRUTINIB

Patent cliffs, clinical trials, pipeline data, AI-enriched regulatory signals — free on PharmaSignal.

OPEN PLATFORM →